Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Chief Executive Officer Craig Collard said the company entered 2026 w
Heron Therapeutics reported mixed Q3 2025 results, missing revenue and earnings estimates. Despite strong growth from its Acute Care products, the miss led to a negative market reaction.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
